Current Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2023 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.
Journal Article JTO Clin Res Rep · November 2025 INTRODUCTION: Immunotherapy has revolutionized the treatment of NSCLC. However, trials that led to approval of these agents and ongoing trials often include overly included overly restrictive exclusion criteria, limiting access for a significant proportion ... Full text Link to item CitePerioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.
Journal Article J Immunother Cancer · October 31, 2025 PURPOSE: A recently published phase 2 neoadjuvant trial in patients with early-stage non-small cell lung cancer (NSCLC) (NCT02818920) evaluated the potential efficacy of pembrolizumab administration in the absence of chemotherapy. This communication report ... Full text Link to item CiteNeoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.
Journal Article Cancers (Basel) · June 21, 2025 Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative i ... Full text Link to item CiteRecent Grants
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-Line Treatment, for Common EGFR-Mutated
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2025 - 2030Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Clinical TrialPrincipal Investigator · Awarded by OncoC4 · 2025 - 2029Investigating the impact of intratumoral PCSK9 on antigen presentation in NSCLC
ResearchPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2025 - 2026View All Grants
Education, Training & Certifications
Rostov State Medical University (Russia) ·
2009
M.D.